For decades, 7+3—consisting of cytarabine plus an anthracycline—has been the backbone of induction therapy for fit adults ...
Although survival rates for acute myeloid leukemia (AML) continue to improve, many long-term survivors face persistent ...
Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may ...
The ELN 2024 framework offers better stratification for AP/BP MPN, but gaps remain between intermediate and adverse groups. The study analyzed 211 patients, showing modest response rates and ...
ASH convened a multidisciplinary panel to develop evidence-based guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, focusing on balancing treatment efficacy with ...
DNA methylation profiles in whole blood samples from 77 patients with CN-AML in The Cancer Genome Atlas (LAML cohort) were analyzed. Individual 5’-cytosine-phosphate-guanine-3’ (CpG) sites were ...
Researchers identified ten ferroptosis-related lncRNAs associated with AML prognosis. These lncRNAs were used to construct a prognostic model, effectively predicting patient survival. High-risk ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results